Navigation Links
Pharmasset Reports Fiscal First Quarter 2009 Financial Results
Date:2/9/2009

bination of two oral antiviral molecules to treat hepatitis C virus (HCV) in the absence of interferon. The study will investigate the combination of Pharmasset's R7128 with InterMune's R7227, a protease inhibitor;

-- On January 11, 2009, Pharmasset announced that the company and its development partner, Roche, had agreed with the FDA on the design for a phase 2b trial with R7128, a nucleoside inhibitor of HCV, slated to initiate in the first calendar quarter of 2009;

-- On January 30, 2009, Pharmasset filed an IND for PSI-7851, a nucleotide inhibitor of HCV, with the FDA and expects to initiate a Phase 1 clinical trial to study safety and pharmacokinetics in healthy volunteers at the end of the first calendar quarter of 2009;

-- On January 30, 2009, Pharmasset and Bukwang Pharm. Co., Ltd. entered into an amendment of their license agreement covering clevudine. The amendment expands the territories in which Pharmasset has been granted rights to include Australia, Japan, New Zealand and Taiwan;

-- On February 5, 2009, Pharmasset completed a registered direct offering that raised net proceeds of $43.5 million.

"We had a very productive start to 2009, filing an IND for PSI-7851, our second generation nucleotide for HCV and, strengthening our balance sheet by raising $43.5 million in a tough financial market" stated Schaefer Price, President and Chief Executive Officer. "Our goal remains to build a leading franchise of nucleoside inhibitors for hepatitis C and B. Our plan is to provide updates throughout the year on all of our programs, including the first antiviral data on PSI-7851 in the second half of 2009."

Calendar Year 2009 Anticipated Milestones:

-- Roche initiates phase 2b study of R7128 in first quarter of 2009;

-- Complete enrollment of clevudine registration trials at end of first quarter of 2009;

-- Initiate
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
2. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
3. Pharmasset to Present at Two Upcoming Investor Conferences
4. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
5. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
6. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
7. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
8. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
9. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
10. Pharmasset Joins Russell 3000 Index
11. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2013)... 19, 2013 Switzerland’s MS Tûranor ... a new speed record for a transatlantic crossing by ... Spain, on April 25, 2013, the solar powered boat ... the average speed of 5.3 knots before reaching Marigot, ... 18, 2013. The first-of-its-kind catamaran completed this year’s passage ...
(Date:5/17/2013)... Oven Industries Inc. announces a new ... controller has many user-friendly benefits. Contained all in one ... as a self-contained temperature control system, which ... the device unique, as well as highly convenient for ... used universally, which allows the user to use the ...
(Date:5/17/2013)... The new Public-Private Partnership (PPP) in Photonics established ... annual meeting drew praise from community leaders from SPIE ... the action “a huge step forward … a lasting ... , The Board of Stakeholders voted to approve in ... its 29 April meeting in Brussels, which was sponsored ...
(Date:5/17/2013)... BEIJING , May 17, 2013  Yongye International, ... "Company"), a leading developer, manufacturer, and distributor of crop ... China , today announced that, on May 16, ... board of directors (the "Board of Directors") was provided ... ( Hong Kong ) Limited ("Abax") to ...
Breaking Biology Technology:MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 2MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 3MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 4MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 5MS Tûranor PlanetSolar Sets World Speed Record for Transatlantic Crossing by Solar Electric Vessel 6New Temperature Control Products Announced by Oven Industries Inc. 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3Yongye International Provides Update on Status of Proposed Go Private Offer 2Yongye International Provides Update on Status of Proposed Go Private Offer 3Yongye International Provides Update on Status of Proposed Go Private Offer 4
... Corporation (NASDAQ: NEOG ) announces the following Webcast: ... When:  Thursday, December 22, 2011 @ 11:00 a.m. ET ... Live over the Internet -- Simply log on to the ... Maynard of Neogen Corporation, +1-800-234-5333. If you are ...
... Pharmaceuticals announces today the termination by Merck Sharp ... of a 2003 agreement, amended in 2006, under ... develop and commercialize anti-ADDL antibody therapeutics and diagnostics ... to discontinue this anti-ADDL Alzheimer,s program and terminate ...
... Bio-AMD, Inc. ("Bio-AMD" or the "Company) (OTCBB: BIAD) ... Strip Reader ("DSR"), one of the three core Point ... 63% owned subsidiary, Bio-AMD Limited. The Company ... lateral flow test strips for multiple diagnostics, particularly in ...
Cached Biology Technology:Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimer's Disease From Merck 2Bio-AMD, Inc.; DSR Commercial Refinement, Prospective Patent Applications 2Bio-AMD, Inc.; DSR Commercial Refinement, Prospective Patent Applications 3
(Date:5/16/2013)... bone marrow in the liver, the spleen or ... that a specific type of immune cell facilitates such ... is essential for the function of the immune system. ... liver and the spleen. Later the process is delegated ... as the sole source of blood cells for the ...
(Date:5/16/2013)... Top neuroscientists from Canada and around the world ... Annual Canadian Neuroscience Meeting will showcase the latest ... system and reveal clues to understanding the disorders ... neuroscience research, and this meeting will showcase the ... the world," says Sam David, President of the ...
(Date:5/16/2013)... Most of us don,t ponder our pulses outside of the ... tool to monitor heart health. , Zhenan Bao, a professor ... thinner than a dollar bill and no wider than a ... bandage on the wrist, is sensitive enough to help doctors ... one day be used to continuously track heart health and ...
Breaking Biology News(10 mins):Herpes infections: Natural killer cells activate hematopoiesis 27th Annual Canadian Neuroscience Meeting, Toronto, May 20-24, 2013 2Stanford engineers monitor heart health using paper-thin flexible 'skin' 2Stanford engineers monitor heart health using paper-thin flexible 'skin' 3
... usually a few square meters in size, where fluid ... Mud volcanoes which are active areas of fluid seepage, ... harsh conditions give rise to some of the most ... on the planet. , Extensive fields of hydrocarbon-rich ...
... through the human body in Fantastic Voyage, doctors might ... a transplant, or to find where and how much ... cell. New technology described in a study published today ... it possible to image and quantify molecules within individual ...
... use to fight viruses is also involved in keeping cancer ... , The anti-viral molecule, called TBK-1, was found to ... might point to a treatment for fighting cancer, the researchers ... got the surprise that this mechanism is involved in cancer ...
Cached Biology News:Life in the extreme 2Fantastic Voyage: A new nanoscale view of the biological world 2Natural anti-viral enzyme helps keep cancer cells alive, researchers find 2
Recombinant Rat Leptin, Ultra Pure...
Lentigen's manufacturing platform is sufficiently versatile for use in the manufacture of any HIV-based Lentiviral vector. Lentigen will manufacture your LV of choice to the highest possible titer a...
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Bethyl Laboratories packages antibodies, conjugates and calibrators to provide quantitative ELISA kits. Each kit contains the following components, sufficient for 1000 single well assays....
Biology Products: